Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
170.38
Nov 20 • 3:59 PM ET Dollar change-4.96 Percentage change(-2.83%)
Aftermarket Close
170.25
Aftermarket • 5:00 PM ET Dollar change-0.13 Percentage change(-0.08%)
Nov 18, 4:50 PMAgilent declares a quarterly cash dividend of 26.25 cents per share, payable January 27, 2027.
Index
S&P 500, RUI
Market Cap
48.04B
Enterprise Value
50.23B
Income
1.44B
Sales
7.37B
Book/sh
26.11
Cash/sh
6.24
Employees
18100
IPO
Nov 18, 1999
P/E
33.55
Forward P/E
25.42
PEG
2.57
P/S
6.52
P/B
6.52
P/C
27.32
P/FCF
37.91
EV/EBITDA
24.54
EV/Sales
6.81
Quick Ratio
1.56
Current Ratio
2.05
Debt/Eq
0.54
LT Debt/Eq
0.50
Option/Short
Yes / Yes
EPS (ttm)
5.08
EPS next Y
6.70
EPS next Q
1.73
EPS this Y
10.94%
EPS next Y
8.07%
EPS next 5Y
9.88%
EPS past 3/5Y
3.03% 14.68%
Sales past 3/5Y
0.48% 5.41%
EPS Y/Y TTM
19.07%
Sales Y/Y TTM
8.60%
EPS Q/Q
8.50%
Sales Q/Q
8.06%
Insider Own
0.32%
Insider Trans
-0.25%
Inst Own
95.52%
Inst Trans
-1.90%
ROA
11.00%
ROE
20.97%
ROIC
13.08%
Gross Margin
53.72%
Oper. Margin
24.09%
Profit Margin
19.53%
SMA20
-2.98%
SMA50
-0.41%
SMA200
22.59%
Trades
Shs Outstand
281.97M
Shs Float
281.04M
52W High
182.99 -6.89%
52W Low
108.35 57.25%
Volatility
2.59% 2.87%
ATR (14)
5.07
RSI (14)
45.63
Beta
1.20
Rel Volume
0.80
Avg Volume
2.34M
Volume
1,882,239
Perf Week
-2.06%
Perf Month
-2.02%
Perf Quarter
11.05%
Perf Half Y
48.21%
Perf YTD
25.21%
Perf Year
17.45%
Perf 3Y
49.48%
Perf 5Y
3.70%
Perf 10Y
278.29%
Prev Close
175.34
Price
170.38
Change %
-2.83%
Consensus
Buy
Avg. Price Target
$184.11
Implied Upside
+8.1%
Analysts17incl. previous ratings
Rating Distribution13 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 26, 2026Initiated
DB logoDDeutsche Bank
Buy$190+11.5%
Sep 09, 2026Resumed
UBS logoUUBS
Neutral$165-3.2%
Jul 09, 2026Resumed
JEF logoJJefferies
Hold$135-20.8%
Jun 26, 2026Resumed
BBernstein
Outperform$155-9.0%
Jun 11, 2026Initiated
PPiper Sandler
Neutral$150-12.0%
May 28, 2026Upgrade
BAC logoBBofA Securities
Neutral → Buy$145-14.9%
May 27, 2026Initiated
RY logoRRBC Capital Mkts
Outperform$153-10.2%
Jan 20, 2026Initiated
HSBC logoHHSBC Securities
Buy$180+5.6%
Jan 05, 2026Upgrade
EVR logoEEvercore ISI
In-line → Outperform$160-6.1%
Dec 15, 2025Upgrade
BCS logoBBarclays
Equal Weight → Overweight$165-3.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dolsten MikaelDirectorSep 04 '26Sale151.3863495,9724,924Sep 09 04:01 PM
Dolsten MikaelDirectorSep 04 '26Proposed Sale151.3863495,972Sep 04 04:19 PM
Dolsten MikaelDirectorMay 29 '26Sale135.421,600216,6725,548Jun 02 04:01 PM
Dolsten MikaelDirectorMay 29 '26Proposed Sale135.421,600216,672May 29 04:45 PM
Dolsten MikaelDirectorDec 01 '25Sale149.812,600389,5114,973Dec 03 04:04 PM
Gonsalves RodneyV.P., Corporate ControllerNov 26 '25Sale154.993,000464,95631,846Dec 01 04:29 PM
Dolsten MikaelDirectorDec 01 '25Proposed Sale149.812,600389,510Dec 01 04:26 PM
Gonsalves RodneyOfficerNov 26 '25Proposed Sale154.993,000464,956Nov 26 02:26 PM
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. The Life Sciences and Diagnostics Markets segment offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. The Applied Markets segment refers to the application-focused solutions that include instruments and software that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products. The Agilent CrossLab segment spans the entire lab with its extensive services and consumables portfolio in addition to software and laboratory automation solutions. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
CEOMr. Padraig McDonnell
Vice President of FinanceMr. Rodney Gonsalves
Senior VP & President of Agilent CrossLab GroupMs. Angelica A. Riemann
Senior VP and President of Life Sciences & Diagnostics Markets GroupDr. Simon May
Special AdvisorMr. Bret M. DiMarco